Skip to main content
. 2016 Oct 3;188(17-18):E447–E455. doi: 10.1503/cmaj.150942

Table 2:

Characteristics of participants and assessment of incident diabetes in the included cohort studies

Study No. of participants % female Age at baseline, yr, mean ± SD Length of follow-up, yr, mean ± SD* Measure of incident diabetes No. of diabetes events Incidence per 10 000 person-years
Open-access data sets
ACL (US)12 1460 52.6 44.4 ± 13.7 12.7 ± 4.2 QS 158 85.2
BCS (UK)13 6473 48.0 33.8 ± 1.9 4.0 ± 0.2 QS 51 19.9
BHPS (UK)14 14 584 52.4 34.1 ± 11.1 6.5 ± 4.0 QS 256 27.6
HILDA (Australia)15 4859 47.8 41.4 ± 12.6 4.0 ± 0.1 QS 77 39.6
MIDUS (US)16 2797 52.2 44.8 ± 10.9 8.9 ± 0.4 QS 173 69.4
NCDS (UK)17 7693 48.1 42.0 ± 0.0 8.3 ± 0.4 QS 207 32.5
WLSG (US)18 4924 50.2 54.1 ± 0.5 11.2 ± 0.3 QS 438 79.7
WLSS (US)19 1980 51.0 51.2 ± 6.3 11.2 ± 0.4 QS 157 70.6
IPD-Work data sets
COPSOQ-I (Denmark)20 1694 48.2 40.7 ± 10.5 12.6 ± 2.0 EMR 45 21.1
COPSOQ-II (Denmark)21 3305 52.6 42.6 ± 10.2 5.9 ± 0.6 EMR 21 10.7
DWECS (Denmark)22 4941 48.9 41.4 ± 10.8 9.8 ± 1.4 EMR 62 12.9
FPS (Finland)23 46 051 81.0 44.5 ± 9.4 9.6 ± 1.1 EMR 1169 26.4
HeSSup (Finland)24 15 434 55.7 39.2 ± 10.2 7.0 ± 0.4 EMR 111 10.3
IPAW (Denmark)25 1665 67.2 41.9 ± 10.6 12.4 ± 1.8 EMR 44 21.4
PUMA (Denmark)26 1865 82.7 42.7 ± 10.3 10.9 ± 1.4 EMR 27 13.3
Still Working (Finland)27 6566 20.5 40.9 ± 9.2 21.1 ± 4.5 EMR 521 37.7
Whitehall II (UK)28 4361 29.4 50.3 ± 4.9 10.2 ± 2.2 CE 306 68.6
WOLF-N (Sweden)29 4593 16.7 43.9 ± 10.3 11.6 ± 1.2 EMR 48 9.0
WOLF-S (Sweden)30 5580 43.3 41.5 ± 11.0 14.5 ± 1.9 EMR 83 10.3
Overall 140 825 58.1 42.2 ± 10.4 9.4 ± 4.0 3954 30.0

Note: CE = clinical examination (oral glucose tolerance test), EMR = electronic medical records, QS = self-reported via repeat questionnaire surveys, SD = standard deviation. See Table 1 for full study names.

*

Mean follow-up time for studies in the Open Access data sets is calculated from the time until the first report of diabetes or the end of follow-up

Incident diabetes measures.